Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;24(9):1888-1893.
doi: 10.1111/dom.14746. Epub 2022 May 25.

A comment on metformin and COVID-19 with regard to "Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy"

Abdallah Al-Salameh  1   2 , Nicolas Wiernsperger  3 , Bertrand Cariou  4 , Jean-Daniel Lalau  1   2
Affiliations

A comment on metformin and COVID-19 with regard to "Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy"

Abdallah Al-Salameh et al. Diabetes Obes Metab. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Abdallah Al‐Salameh reports personal fees from AstraZeneca, Lilly, and Novo Nordisk, none of which related to the subject discussed in this manuscript. Nicolas Wiernsperger declares no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported. Bertrand Cariou reports grants and personal fees from Amgen, personal fees from AstraZeneca, personal fees from Akcea, personal fees from Genfit, personal fees from Gilead, personal fees from Eli Lilly, personal fees from Novo Nordisk, personal fees from MSD, grants and personal fees from Sanofi, and grants and personal fees from Regeneron. Jean‐Daniel Lalau reports personal fees from AstraZeneca, Brothier, Lilly, MSD, Novo Nordisk, Pfizer, and Sanofi.

References

    1. Ojeda‐Fernández L, Foresta A, Macaluso G, et al. Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID‐19 patients with diabetes: a population‐based study in Lombardy. Diabetes Obes Metab. 2022;24(5):891‐898. doi:10.1111/dom.14648 - DOI - PubMed
    1. Cernigliaro A, Allotta AV, Scondotto S. Can diabetes and its related hypoglycemic drug treatment be considered risk factors for health outcomes in COVID‐19 patients? The results of a study in the population residing in Sicily region (southern Italy). Epidemiol Prev. 2020;44(5‐6 Suppl 2):315‐322. doi:10.19191/EP20.5-6.S2.132 - DOI - PubMed
    1. Khunti K, Knighton P, Zaccardi F, et al. Prescription of glucose‐lowering therapies and risk of COVID‐19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9(5):293‐303. doi:10.1016/S2213-8587(21)00050-4 - DOI - PMC - PubMed
    1. Bramante CT, Buse J, Tamaritz L, et al. Outpatient metformin use is associated with reduced severity of COVID‐19 disease in adults with overweight or obesity. J Med Virol. 2021;93(7):4273‐4279. doi:10.1002/jmv.26873 - DOI - PMC - PubMed
    1. Ghany R, Palacio A, Dawkins E, et al. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. Diabetes Metab Syndr. 2021;15(2):513‐518. doi:10.1016/j.dsx.2021.02.022 - DOI - PMC - PubMed

MeSH terms